UK cost agency says "no" to Novartis blood cancer drug Jakavi

LONDON Tue Feb 12, 2013 7:24pm EST

Related Topics

LONDON (Reuters) - A new drug from Novartis for myelofibrosis, a rare blood cancer, is not worth using on the state health service, Britain's healthcare cost watchdog said on Wednesday.

The National Institute for Health and Clinical Excellence (NICE) said it had issued new draft guidance not recommending Jakavi because it could not be considered a cost-effective use of resources.

The drug costs 3,600 pounds ($5,600) for a 60-tablet pack, corresponding to an annual cost of approximately 43,200 pounds per patient.

Jakavi, which was licensed from Incyte, was given a marketing authorization in Europe last August.

Industry analysts expect it to have annual worldwide sales of around $1.5 billion by 2017, according to consensus forecasts compiled by Thomson Reuters Pharma.

The NICE draft guidance is now out for consultation, ahead of a final decision on the medicine expected in June.

(Reporting by Ben Hirschler; Editing by Greg Mahlich)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (2)
tnourie wrote:
I smell greed. Smells bad, like a crippling lawsuit. The lawsuit the surviving members of the condemned family should bring about to destroy Novartis as a business entity.

Novartis is passing a death sentence on people for reasons of pure greed. This is unconscionable.

Anyone who is denied this lifesaving drug due to “cost” should sue Novartis and the insurance provider, whoever they may be. While Novartis has a right to recoup costs, they do not have the right to cast a death sentence on someone because they aren’t rich enough to afford this overpriced lifesaving “device”.

Feb 13, 2013 4:40pm EST  --  Report as abuse
tnourie wrote:
>>Your comment will appear shortly. We will refrain from publishing comments that do not meet our standards.

Feb 13, 2013 4:43pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.